GFAP and Alexander disease: In agreement with the targetable pharmacological mechanisms known to be effective in AxD, the small molecules taken into consideration in the present work seem to act mainly by modulation of GFAP gene expression and induction of HSPs such as αB-crystallin, as summarized in Table 2.